Leonard Philip James
Pfizer (United States) · 38 works · 4,757 citations · h-index 18
Top works
- The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
- Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes
- Metalloregulation in Bacillus subtilis: isolation and characterization of two genes differentially repressed by metal ions
- Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo
- Reproducibility of computed tomography (CT) measurements of lung cancer
- Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).
- Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.
- Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
- Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.
- The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
- Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial